Evidence map›Paper›PMID 35780715›Full record

ArticleGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society2022

Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Stephanie A Osganian, Sonu Subudhi, Ricard Masia, Hannah K Drescher, Lea M Bartsch, Mark L Chicote, Raymond T Chung, Denise W Gee, Elan R Witkowski, Miriam A Bredella and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Metabolic Health and Disease: A Role of Osteokines?Calcified tissue international · 2023
    Review
  10. Growth hormone and nonalcoholic fatty liver disease.Immunometabolism (Cobham, Surrey) · 2023 · on this map
    Review
  11. Article
  12. Important Hormones Regulating Lipid Metabolism.Molecules (Basel, Switzerland) · 2022
    Review
  13. CT Texture Analysis in Nonalcoholic Fatty Liver Disease (NAFLD).Journal of clinical and experimental hepatology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Stephanie A OsganianLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA.
Sonu SubudhiLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA; Harvard Medical School (HMS), Boston, MA, USA.
Ricard MasiaHarvard Medical School (HMS), Boston, MA, USA; Department of Pathology, MGH, Boston, MA, USA.
Hannah K DrescherLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA; Harvard Medical School (HMS), Boston, MA, USA.
Lea M BartschLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA; Harvard Medical School (HMS), Boston, MA, USA.
Mark L ChicoteNeuroendocrine Unit, MGH, Boston, MA, USA.
Raymond T ChungLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA; Harvard Medical School (HMS), Boston, MA, USA.
Denise W GeeHarvard Medical School (HMS), Boston, MA, USA; Department of Surgery, MGH, Boston, MA, USA.
Elan R WitkowskiHarvard Medical School (HMS), Boston, MA, USA; Department of Surgery, MGH, Boston, MA, USA.
Miriam A BredellaHarvard Medical School (HMS), Boston, MA, USA; Department of Radiology, Division of Musculoskeletal Radiology and Interventions, MGH, Boston, MA, USA.
Georg M LauerLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA; Harvard Medical School (HMS), Boston, MA, USA.
Kathleen E CoreyLiver Center, Division of Gastroenterology, Massachusetts General Hospital (MGH), Boston, MA, USA; Harvard Medical School (HMS), Boston, MA, USA.
Laura E DichtelHarvard Medical School (HMS), Boston, MA, USA; Neuroendocrine Unit, MGH, Boston, MA, USA. Electronic address: ldichtel@partners.org.
Harvard University · USMassachusetts General Hospital · USMGH Institute of Health Professions · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI LOWELL, BRADFORD B · 1992 to 2021
$25.0M
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisK23DK113220 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DICHTEL, LAURA ELISABETH · 2017 to 2021
$1.1M
Bone Metabolism in Adolescents UndergoingBariatric SurgeryK24DK109940 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BREDELLA, MIRIAM ANTOINETTE · 2017 to 2021
$970k
NCATS NIH HHS UL1 TR001102NIDDK NIH HHS K23 DK113220NIDDK NIH HHS K24 DK109940NIDDK NIH HHS P30 DK046200
6 · The paper itself

Abstract

objectiveThe GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor (GHR) expression in adult, human hepatic tissue is not well understood across the spectrum of NAFLD severity. Therefore, we sought to investigate hepatic IGF-1R and GHR expression in subjects with NAFLD utilizing gene expression analysis (GEA) and immunohistochemistry (IHC).

designGEA (n = 318) and IHC (n = 30) cohorts were identified from the Massachusetts General Hospital NAFLD Tissue Repository. GEA subjects were categorized based on histopathology as normal liver histology (NLH), steatosis only (Steatosis), nonalcoholic steatohepatitis (NASH) without fibrosis (NASH F0), and NASH with fibrosis (NASH F1-4) with GEA by the Nanostring nCounter assay. IHC subjects were matched for age, body mass index (BMI), sex, and diabetic status across three groups (n = 10 each): NLH, Steatosis, and NASH with fibrosis (NASH F1-3). IHC for IGF-1R, IGF-1 and GHR was performed on formalin-fixed, paraffin-embedded hepatic tissue samples.

resultsIGF-1R gene expression did not differ across NAFLD severity while IGF-1 gene expression decreased with increasing NAFLD severity, including when controlled for BMI and age. GHR expression did not differ by severity of NAFLD based on GEA or IHC.

conclusionsIGF-1R and GHR expression levels were not significantly different across NAFLD disease severity. However, expression of IGF-1 was lower with increasing severity of NAFLD. Additional research is needed regarding the contribution of the GH/IGF-1 axis to the pathophysiology of NAFLD and NASH.

Indexed as

Non-alcoholic Fatty Liver DiseaseAdultFibrosisHumansInsulin-Like Growth Factor ILiverReceptor, IGF Type 1Insulin-Like Growth Factor IReceptor, IGF Type 1Gene expression analysisGH receptorGrowth hormone (GH)IGF-1 receptorImmunohistochemistryInsulin-like growth factor-1 (IGF-1)Nonalcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)

Identifiers

PMID35780715
PMCPMC9885486
OpenAlexW4283121302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.